Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation
Keith W. Pratz(University of Pennsylvania), Mark J. Levis(Sidney Kimmel Cancer Center), Vu H. Duong(University of Maryland, Baltimore), Michelle A. Rudek(Dana-Farber Cancer Institute), Ashkan Emadi(University of Maryland, Baltimore), Christopher D. Gocke, Jackie Greer(Sidney Kimmel Comprehensive Cancer Center), Judith E. Karp(Emory University), Ivana Gojo(Johns Hopkins University), Maria R. Baer(University of Maryland, Baltimore), Leo Luznik(Johns Hopkins University), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), B. Douglas Smith(Johns Hopkins University)
Cited by 28
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Increase in<i>Candida krusei</i>Infection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole
|New England Journal of Medicine|1991|947